Cancer Biologics Market By Product Type (Monoclonal Antibodies, Cancer Vaccines, Cytokines, Gene Therapy, Cell Therapy), By Application (Immunotherapy, Targeted Therapy, Chemotherapy), By End-User Industry (Hospitals, Cancer Research Institutes, Biopharmaceutical Companies), By Therapeutic Area (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Leukemia, Lymphoma); Global Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Cancer Biologics Market was valued at USD 87.1 billion in 2023 and will surpass USD 164.9 billion by 2030; growing at a CAGR of 9.5% during 2024 - 2030. The cancer biologics market is growing rapidly, driven by the demand for advanced, targeted therapies designed to treat a wide range of cancers. With the development of biologic drugs, including monoclonal antibodies, cancer vaccines, gene therapies, and cell therapies, the market has seen an increase in personalized treatment options. The focus has shifted towards using these biologics to not only improve treatment outcomes but also reduce side effects associated with traditional chemotherapy. Innovations in immunotherapy and the continued research into advanced cancer treatments have significantly contributed to the expansion of this market. As healthcare providers and researchers continue to discover new ways to harness the immune system and other biological mechanisms to combat cancer, the demand for biologic therapies continues to rise. Product Type Segment is Largest Owing to the Dominance of Monoclonal Antibodies Monoclonal antibodies (mAbs) represent the largest subsegment in the cancer biologics market, owing to their proven efficacy in treating various types of cancers. These antibodies are engineered to target specific proteins found on cancer cells, making them highly effective in inhibiting tumor growth. Monoclonal antibodies have become a cornerstone of modern cancer treatment, with drugs like Herceptin (trastuzumab) and Rituxan (rituximab) showing significant success in treating cancers such as breast cancer and lymphoma. The widespread adoption of monoclonal antibodies can be attributed to their versatility, as they are effective in treating multiple types of cancers, including solid tumors and hematological malignancies. Moreover, they can be used in combination with other therapies, such as chemotherapy and immunotherapy, for enhanced therapeutic outcomes. The ongoing development of next-generation monoclonal antibodies with improved targeting capabilities and fewer side effects further solidifies the dominance of this product type in the market. Application Segment is Fastest Growing Owing to the Surge in Immunotherapy Adoption Immunotherapy is the fastest-growing application segment in the cancer biologics market, driven by its ability to harness the body’s immune system to fight cancer. Immunotherapies, such as checkpoint inhibitors and CAR-T cell therapies, are revolutionizing cancer treatment by enhancing the immune system's ability to recognize and destroy cancer cells. The success of immunotherapies in treating cancers that were previously considered difficult to treat, such as melanoma and non-small cell lung cancer, has led to an increased focus on these treatments within the oncology community. The growing demand for immunotherapy is further supported by its potential for long-term remission, making it an attractive alternative to traditional cancer treatments like chemotherapy. With continuous advancements in immunotherapy technologies, including personalized treatments tailored to individual genetic profiles, the segment is expected to grow exponentially. Immunotherapy’s proven efficacy, coupled with its potential to provide durable responses, positions it as a key player in the future of cancer treatment. End-User Industry Segment is Largest in Hospitals Due to High Patient Volume and Treatment Demand Hospitals are the largest end-user industry for cancer biologics, largely due to their role in treating a broad range of cancer patients. Hospitals, especially large cancer centers and research institutions, provide specialized care and access to cutting-edge biologic therapies, which are crucial for treating both early and advanced stages of cancer. The ability to administer biologic drugs like monoclonal antibodies and immunotherapies in hospital settings ensures that patients receive the necessary monitoring and support throughout the treatment process. The increasing number of cancer patients, along with advancements in biologic treatments, has driven the demand for biologic drugs in hospital settings. Hospitals are also involved in the clinical trials for new cancer biologics, which helps accelerate the approval of innovative therapies. As the cancer biologics market grows, hospitals will continue to be the primary channel for the distribution and administration of these life-saving therapies, contributing significantly to the overall market expansion. Therapeutic Area Segment is Largest in Breast Cancer Owing to the High Incidence Rate and Targeted Therapies Breast cancer is the largest therapeutic area within the cancer biologics market, primarily due to its high incidence rate and the availability of targeted biologic therapies. Monoclonal antibodies like Herceptin (trastuzumab) and Perjeta (pertuzumab) have been pivotal in improving the treatment outcomes for HER2-positive breast cancer, significantly enhancing survival rates. Additionally, immunotherapy has started to play a role in the treatment of breast cancer, particularly in triple-negative breast cancer, which is typically more difficult to treat with traditional therapies. The high demand for biologics in breast cancer treatment is also driven by the growing awareness of early detection and advancements in personalized medicine. With continuous improvements in biologic therapies and the potential for new treatments, the breast cancer segment is expected to continue leading the market. Moreover, the development of combination therapies that integrate biologics with chemotherapy and immunotherapy is further fueling the market's growth in this therapeutic area. Fastest Growing Region is Asia Pacific Due to Rapid Healthcare Advancements and Rising Cancer Incidences The Asia Pacific (APAC) region is experiencing the fastest growth in the cancer biologics market. Factors such as the increasing incidence of cancer, improvements in healthcare infrastructure, and a growing focus on biologic treatments are driving this growth. In countries like China, India, and Japan, the demand for cancer biologics is rising rapidly as healthcare providers invest in advanced therapies to address the increasing cancer burden. The rise of medical tourism in the region, along with growing government support for cancer treatment initiatives, further contributes to the rapid adoption of biologic drugs. APAC's growth in the cancer biologics market is also supported by the region's expanding biopharmaceutical industry, which is increasingly focusing on developing biologic therapies tailored to the needs of local populations. As the region continues to modernize its healthcare systems and increase access to biologic treatments, it is expected to become a major contributor to the global cancer biologics market in the coming years. Leading Companies and Competitive Landscape The cancer biologics market is highly competitive, with numerous global players driving innovation and market growth. Leading companies in the market include Amgen, Bristol-Myers Squibb, Roche, Merck & Co., and Novartis. These companies dominate the market through their strong portfolios of monoclonal antibodies, cancer vaccines, and other biologic treatments. Their continuous investment in research and development, along with strategic partnerships and acquisitions, enables them to maintain a competitive edge in this rapidly evolving market. In addition to established pharmaceutical giants, a growing number of biotech firms are entering the market, contributing to the increasing availability of novel cancer biologics. The competitive landscape is also shaped by the growing trend of personalized medicine, which is driving the development of biologics that are tailored to the genetic profiles of individual patients. As new treatments enter the market, the focus on improving efficacy, reducing side effects, and lowering costs will continue to intensify competition among market players. Recent Developments: • Bristol-Myers Squibb announced the FDA approval of a new combination immunotherapy for advanced melanoma, increasing the company’s portfolio in cancer treatment. • Roche launched a new monoclonal antibody for the treatment of lung cancer, showing promising results in clinical trials for improving survival rates in patients with non-small cell lung cancer. • Merck & Co. acquired a biotechnology company focused on cell therapy for oncology, expanding its pipeline of innovative cancer treatments. • Novartis received regulatory approval for its new cancer vaccine targeting prostate cancer, marking a significant milestone in immuno-oncology. • Gilead Sciences entered into a partnership with a leading cancer research institute to develop advanced gene therapies for leukemia and lymphoma treatment. List of Leading Companies: • Amgen • Bristol-Myers Squibb • Roche • Merck & Co. • Novartis • Johnson & Johnson • Eli Lilly • AstraZeneca • Sanofi • AbbVie • Regeneron Pharmaceuticals • Gilead Sciences • Takeda Pharmaceutical • Celgene (now part of Bristol-Myers Squibb) • GlaxoSmithKline Report Scope: Report Features Description Market Size (2023) USD 87.1 Billion Forecasted Value (2030) USD 164.9 Billion CAGR (2024 – 2030) 9.5% Base Year for Estimation 2023 Historic Year 2022 Forecast Period 2024 – 2030 Report Coverage Market Forecast, Market Dynamics, Competitive Landscape, Recent Developments Segments Covered Cancer Biologics Market By Product Type (Monoclonal Antibodies, Cancer Vaccines, Cytokines, Gene Therapy, Cell Therapy), By Application (Immunotherapy, Targeted Therapy, Chemotherapy), By End-User Industry (Hospitals, Cancer Research Institutes, Biopharmaceutical Companies), By Therapeutic Area (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Leukemia, Lymphoma) Regional Analysis North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, South Korea, Australia, India, and Rest of Asia-Pacific), Latin America (Brazil, Argentina, and Rest of Latin America), Middle East & Africa (Saudi Arabia, UAE, Rest of Middle East & Africa) Major Companies Amgen, Bristol-Myers Squibb, Roche, Merck & Co., Novartis, Johnson & Johnson, Eli Lilly, AstraZeneca, Sanofi, AbbVie, Regeneron Pharmaceuticals, Gilead Sciences, Takeda Pharmaceutical, Celgene (now part of Bristol-Myers Squibb), GlaxoSmithKline Customization Scope Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements